|

JAB-3312 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Allist Pharmaceuticals, Inc.2

Indications

  • Lung Cancer2
  • Cancer2
  • Pancreatic Ductal Carcinoma1
  • KRAS P.G12C1
  • Metastatic Non-squamous Non Small Cell Lung Cancer1

Other2 trials

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Phase 3
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.